Lumos Pharma, Inc. (LUMO) |
| 4.34 0 (0%) 12-11 16:00 |
| Open: | 4.33 |
| High: | 4.34 |
| Low: | 4.33 |
| Volume: | 390,873 |
| Market Cap: | 38(M) |
| PE Ratio: | -1.01 |
| Exchange: | NASDAQ Global Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 8.89 |
| Resistance 1: | 7.85 |
| Pivot price: | 6.70 |
| Support 1: | 6.16 |
| Support 2: | 5.13 |
| 52w High: | 4.5756 |
| 52w Low: | 1.3701 |
Lumos Pharma, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to advancing and commercializing medical treatments for rare conditions. Their principal therapeutic compound, LUM-201, an orally administered growth hormone secretagogue called ibutamoren, is currently undergoing Phase 2 clinical evaluation. This drug candidate is being investigated for its potential in treating pediatric growth hormone deficiency and various other uncommon endocrine conditions. The company's operations are based in Austin, Texas.
Financials
| EPS | -1.750 |
| Book Value | -1.280 |
| PEG Ratio | 17.14 |
| Gross Profit | 5.563 |
| Profit Margin (%) | -14.34 |
| Operating Margin (%) | -0.69 |
| Return on Assets (ttm) | -0.8 |
| Return on Equity (ttm) | 0.0 |
Company news
Mon, 13 Jul 2026
Telesis Bio - DNAY - Stock Price & News - The Motley Fool
Thu, 12 Dec 2024
Lumos Pharma Completes Successful Tender Offer and Merger with Double Point Ventures - Quiver Quantitative
Thu, 24 Oct 2024
DPV set to acquire Lumos Pharma for $38m - Pharmaceutical Technology
Wed, 22 May 2024
Sarah Alexander Net Worth (2026) - GuruFocus
Sun, 04 Dec 2022
Bradley J Powers Net Worth (2026) - GuruFocus
Tue, 15 Dec 2020
Lumos Pharma Stock Price Forecast. Should You Buy LUMO? - StockInvest.us
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
